Insmed (INSM) Financial Analysis & Valuation | Quarter Chart
Insmed (INSM)
INSMPrice: $139.52
Fair Value: 🔒
🔒score
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is... more
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients... more
Description
Shares
| Market Cap | $30.07B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Pharmaceuticals |
| Country | US | CEO | William H. Lewis |
| IPO Date | 2000-06-01 | CAGR | 0.29% |
| Employees | 1,271 | Website | www.insmed.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
INSM chart loading...
Fundamentals
Technicals
| Enterprise Value | $19.93B | P/E Ratio | -21.73 |
| Forward P/E | 192.87 | PEG Ratio | — |
| P/S Ratio | 0.01 | P/B Ratio | 0.01 |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $-6.42 | EPS Growth 1Y | 11.53% |
| EPS Growth 3Y | 70.05% | EPS Growth 5Y | 138.08% |
| Revenue Growth 1Y | 30.34% | Gross Margin | 0.76% |
| Operating Margin | -2.46% | Profit Margin | -2.65% |
| ROE | -1.84% | ROA | -0.5% |
| ROCE | -0.57% | Current Ratio | 4.63 |
| Quick Ratio | 4.34 | Cash Ratio | 0.8 |
| Debt/Equity | 0.04 | Interest Coverage | -12.96 |
| Altman Z Score | 9.41 | Piotroski Score | 3 |